Sia, Z.R., et al. Preparing Adjuvanted Nanoliposomes for Applications Toward Recombinant Influenza Vaccine Development. Bio Protoc, 2026 Apr 5, 16(7):e5662. PMID: 41971165
This paper, closely related to the previous one, presents a novel platform for
developing recombinant influenza vaccines using adjuvanted nanoliposomes that
incorporate saponin-based adjuvants, specifically QS-21, within the lipid bilayer. The
unique aspect of this approach is the surface decoration of liposomes with His-
tagged recombinant hemagglutinin antigens via cobalt-porphyrin phospholipids,
enabling rapid and customizable vaccine formulations without the need for traditional
egg-based virus cultivation. The background underscores the challenges of
conventional influenza vaccine production, including long manufacturing times, egg
supply limitations, and mutations introduced during egg adaptation. By integrating saponin QS-21 into liposomes, this method leverages its proven ability to enhance
cellular immunity and antigen uptake, offering a flexible, scalable, and potentially
more effective alternative for universal and multistrain influenza vaccines. The
importance lies in its potential to improve vaccine efficacy, adaptability, and
production speed, the critical factors in responding to rapidly evolving viral threats
and pandemics.
This study demonstrates that the adjuvanted nanoliposome platform incorporating
QS-21 effectively facilitates the surface display of recombinant influenza
hemagglutinin antigens via His-tag binding, leading to the formation of immunogenic
vaccine particles. The researchers successfully produced liposomes approximately
100 nm in diameter with incorporated lipid adjuvants, including QS-21, and
confirmed strong antigen binding and stability. Functional assays, including ELISA
and hemagglutination inhibition tests, verified that these liposome-bound antigens
elicited robust immune responses, showcasing their potential for inducing protective
immunity.
Overall, the findings validate the platform’s versatility, rapid production capability,
and its promising role in enhancing antigen-specific immune responses,
emphasizing its potential application in next-generation influenza vaccines. However,
some limitations of the study include that the data were obtained from preclinical in
vitro and animal studies, which may not fully predict outcomes in humans; the long-
term stability of the liposomal formulations requires further evaluation; and scalability
and manufacturing consistency have not been addressed.
Click here to access the full scientific paper.
